Successful Management of Acquired von Willebrand Syndrome Associated with Monoclonal Gammopathy of Undetermined Significance After Sotorasib Treatment in a Patient with Non-Small-Cell Lung Carcinoma DOI Creative Commons

Mélissa Julien,

Léa Pierre,

Anne‐Cécile Gerout

и другие.

Hematology Reports, Год журнала: 2025, Номер 17(2), С. 21 - 21

Опубликована: Апрель 16, 2025

Background: This case report investigates the effects of sotorasib treatment in a patient with acquired von Willebrand syndrome (AVWS) associated monoclonal gammopathy undetermined significance (MGUS), who subsequently developed non-small-cell lung carcinoma (NSCLC) KRAS G12C mutation. Case Presentation: The patient, 79-year-old male, presented prolonged history recurrent lower gastrointestinal bleeding attributed to digestive angiodysplasia, which had persisted for over 30 years. AVWS was suspected based on qualitative deficiency factor (VWF), abnormal results VIII activity (FVIII:C), VWF antigen (VWF:Ag), and ristocetin cofactor (VWF:Rco) (40%, 20%, <2.4%, respectively). Further evaluation revealed presence an IgM kappa spike, suggesting MGUS. In 2022, diagnosed NSCLC harboring mutation initiated second-line sotorasib. Notably, one year after initiation therapy, patient’s hemostasis normalized, accompanied by significant improvements levels. multimer electrophoresis demonstrated restoration high-molecular-weight multimers (HMWMs), serum protein no longer detected Conclusion: These were likely attributable indirect bone marrow microenvironment. By inhibiting stromal cells osteoclasts, may have disrupted supportive niche necessary malignant plasma cell survival, resulting reduction spike. Unfortunately, eventually succumbed carcinogenic pleurisy.

Язык: Английский

Insights into the Molecular Mechanisms and Nanoparticle-Based Therapies for Gastric Cancer: A review DOI Creative Commons

Smarika Chauhan,

Eswar Marcharla,

Sneha Hariharan

и другие.

Results in Engineering, Год журнала: 2025, Номер unknown, С. 104238 - 104238

Опубликована: Фев. 1, 2025

Язык: Английский

Процитировано

0
Metformin combined with CB-839 specifically inhibits KRAS-mutant ovarian cancer DOI Creative Commons

Han Wu,

Jialin Zhang, Qiujie Wang

и другие.

Scientific Reports, Год журнала: 2025, Номер 15(1)

Опубликована: Фев. 19, 2025

KRAS mutations can cause metabolic reprogramming in ovarian cancer, leading to an increased metastatic capacity. This study investigated the changes induced by cancer and mechanism of action metformin combined with a glutaminase 1 inhibitor (CB-839). KRAS-mutant accounted for 14% cancers. The expression glucose metabolism-related (PFKFB3, HK2, GLUT1, PDK2) glutamine enzymes (GLS1 ASCT2) was elevated cells compared that wild-type cells. had higher aerobic oxidative capacity than did Metformin inhibited proliferation, enzymes, those control Furthermore, it enhanced CB-839 proliferation oxidation greater extent observed Additionally, inhibitory effects NOD-SCID mouse model were significantly stronger drug-alone group. lead metabolism cells, which CB-839.

Язык: Английский

Процитировано

0
Unraveling the anoikis-cancer nexus: a bibliometric analysis of research trends and mechanisms DOI Creative Commons
Junjie Jiang, Wei Peng, Nianzhe Sun

и другие.

Future Science OA, Год журнала: 2025, Номер 11(1)

Опубликована: Март 31, 2025

Background Cancer, influenced by genetics and the environment, involves anoikis, a cell death mechanism upon extracellular matrix detachment crucial for metastasis. Understanding this relationship is key therapy. We analyze cancer anoikis trends using bibliometrics.

Язык: Английский

Процитировано

0
Successful Management of Acquired von Willebrand Syndrome Associated with Monoclonal Gammopathy of Undetermined Significance After Sotorasib Treatment in a Patient with Non-Small-Cell Lung Carcinoma DOI Creative Commons

Mélissa Julien,

Léa Pierre,

Anne‐Cécile Gerout

и другие.

Hematology Reports, Год журнала: 2025, Номер 17(2), С. 21 - 21

Опубликована: Апрель 16, 2025

Background: This case report investigates the effects of sotorasib treatment in a patient with acquired von Willebrand syndrome (AVWS) associated monoclonal gammopathy undetermined significance (MGUS), who subsequently developed non-small-cell lung carcinoma (NSCLC) KRAS G12C mutation. Case Presentation: The patient, 79-year-old male, presented prolonged history recurrent lower gastrointestinal bleeding attributed to digestive angiodysplasia, which had persisted for over 30 years. AVWS was suspected based on qualitative deficiency factor (VWF), abnormal results VIII activity (FVIII:C), VWF antigen (VWF:Ag), and ristocetin cofactor (VWF:Rco) (40%, 20%, <2.4%, respectively). Further evaluation revealed presence an IgM kappa spike, suggesting MGUS. In 2022, diagnosed NSCLC harboring mutation initiated second-line sotorasib. Notably, one year after initiation therapy, patient’s hemostasis normalized, accompanied by significant improvements levels. multimer electrophoresis demonstrated restoration high-molecular-weight multimers (HMWMs), serum protein no longer detected Conclusion: These were likely attributable indirect bone marrow microenvironment. By inhibiting stromal cells osteoclasts, may have disrupted supportive niche necessary malignant plasma cell survival, resulting reduction spike. Unfortunately, eventually succumbed carcinogenic pleurisy.

Язык: Английский

Процитировано

0